z-logo
open-access-imgOpen Access
Deterioration of bladder compliance after botulinum toxin A injection and discontinuation of medication for overactive bladder
Author(s) -
Wada Naoki,
Ishikawa Mayumi,
Nagabuchi Masaya,
Makino Shogo,
Miyauchi Kotona,
Abe Noriyuki,
Kakizaki Hidehiro
Publication year - 2022
Publication title -
iju case reports
Language(s) - English
Resource type - Journals
ISSN - 2577-171X
DOI - 10.1002/iju5.12496
Subject(s) - overactive bladder , medicine , botulinum toxin , discontinuation , urology , surgery , pathology , alternative medicine
We report a case of deterioration of bladder compliance after botulinum toxin type A injection and discontinuation of medication for overactive bladder. Case presentation A female patient with overactive bladder in her sixties had been visiting our outpatient clinic regularly for 4 years. She had received posterolateral spondylus fusion twice, which resulted in a compression fracture. She had been receiving a combination therapy of anticholinergics and β3‐adrenoceptor agonist for the management of overactive bladder. She received botulinum toxin type A injection for refractory overactive bladder and discontinued medical treatment for overactive bladder. Three months after botulinum toxin type A injection, cystometry revealed the deterioration of bladder compliance. Renal dysfunction, hydronephrosis, and vesicoureteral reflux were shown. Renal function and hydronephrosis were improved after restarting anticholinergics and β3‐adrenoceptor agonist therapy and inserting a temporary transurethral catheter. Conclusion Deterioration of bladder compliance may occur after botulinum toxin type A injection and discontinuation of overactive bladder medication in some patients with underlying neurological disease.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here